RBC Capital Assumes Aquestive Therapeutics (AQST) at Outperform

April 6, 2021 4:27 PM EDT
Get Alerts AQST Hot Sheet
Price: $1.06 -4.5%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 9 | New: 24
Join SI Premium – FREE

RBC Capital analyst Daniel Busb assumes coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Outperform rating and a price target of $7.00.

For an analyst ratings summary and ratings history on Aquestive Therapeutics click here. For more ratings news on Aquestive Therapeutics click here.

Shares of Aquestive Therapeutics closed at $5.21 yesterday.

You May Also Be Interested In

Related Categories

New Coverage